Effects of long-term treatment of linagliptin on glycemic control and serum lipids in patients with type 2 diabetes

Effects of long-term treatment of linagliptin on glycemic control and serum lipids in patients with type 2 diabetes - Effects of linagliptin on glycemic control and serum lipids

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018652

Enrollment

Registered

2015-08-12

Start date

2011-10-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Administration of 5 mg/day linagliptin for 18 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients. Obtained written informed consent from the patients before participation.

Exclusion criteria

Exclusion criteria: Complicated severe nephropathy.

Design outcomes

Primary

Measure	Time frame
Hemoglobin A1c level, serum levels of total, HDL, and LDL cholesterol and triglyceride on 18 mo after the intervention	—

Secondary

Measure	Time frame
Casual blood glucose level on 18 mo after the intervention	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

info@tonyo.jp052-789-3946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026